ReviewDiscover oncology2026
Advances of curcumin-loaded hydrogels for multimodal cancer therapeutics.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Curcumin-loaded PEGylated Magnetic Iron Oxide Nanoparticles: a Biogenic Platform for Targeted and Controlled Drug Release.Applied biochemistry and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Curcumin, a natural polyphenol with multifaceted anticancer properties, faces significant clinical translation challenges due to poor solubility, rapid metabolism, and low bioavailability. Hydrogels, as biocompatible and tunable drug delivery platforms, have emerged as a transformative strategy to overcome these limitations. This review highlights recent advancements in curcumin-hydrogel systems, emphasizing stimuli-responsive designs (e.g., pH-, temperature-, and light-activated mechanisms), combinatorial therapies, and applications across diverse cancer models. Innovations such as miRNA co-delivery, metallo-pharmaceutical hybrids, and dual-functional hydrogels with antimicrobial activity are explored, demonstrating enhanced spatiotemporal control, targeted delivery, and synergistic therapeutic outcomes. Combinatorial approaches integrating curcumin with chemotherapeutics, photothermal agents, or epigenetic modulators amplify anticancer efficacy by simultaneously disrupting oncogenic pathways and reversing chemoresistance. Compared with existing reviews, this work provides a comprehensive synthesis of emerging intelligent hydrogel technologies-including AI-integrated predictive release systems, multi-stimuli-responsive platforms, and CRISPR-immunotherapy hybrids-specifically within the context of cancer therapy, thereby systematically linking advanced material design with multimodal treatment strategies. Despite these advancements, challenges such as pH-dependent degradation, formulation stability, and clinical scalability persist. The review also emphasizes the paradigm-shifting potential of systems enabling precision targeting of chemoresistant tumors while modulating immune checkpoints.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.